CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Evaluate the safety and tolerability of AMG 509 in adult participants and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2...
Phase 1
Taipei, Taiwan and 52 other locations
To evaluate the effect of MCS® compared with placebo in reducing the risk of biopsy-detectable prostate cancer in high-risk subject...
Phase 2
Taipei, Taiwan
therapy in participants with metastatic castration resistant prostate cancer (mCRPC). There will be ten cohorts in this study: Coho...
Phase 1, Phase 2
Taipei, Taiwan and 27 other locations
plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the doce...
Phase 3
Taipei, Taiwan and 216 other locations
The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate...
Phase 3
Taipei, Taiwan and 388 other locations
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutam...
Phase 2
Taipei, Taiwan and 234 other locations
in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy (RT) results in a...
Phase 3
Taipei, Taiwan and 271 other locations
survival (rPFS) per 1) Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for soft tissue and/or Prostate Cancer Wo...
Phase 3
Taipei, Taiwan and 322 other locations
vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to ...
Phase 3
Taipei, Taiwan and 63 other locations
and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate...
Phase 3
Taipei, Taiwan and 130 other locations
Clinical trials
Research sites
Resources
Legal